Skip to main content
ScholarsBetaWeill Cornell Medicine

Highlights

  1. 1
    Transplantation and cellular therapy · 2023
    NGNitya GulatiLGLisa Giulino Roth
    PMID: 37914501DOIFirst author3 citations
  2. 2
    Pediatric hematology and oncology · 2020
    NGNitya Gulati
    PMID: 33439096DOIFirst and senior author1 citations
  3. 3
    Blood advances · 2025
    NGNitya Gulati
    PMID: 39883450PMCID: PMC11881743DOIFirst author

Publications

29 publications

Funding

7 grants

Active

7 grants
  • KP
    COG NCTN Network Group Operations Center
    National Cancer Institute · 2026–2032 · via Children's Oncology Group
    U10CA180886-12
  • PI
    Phase 2 study of Tovorafenib (Day 101) in Relapsed and Refractory Langerhans Cell Histiocytosis
    Medical College of Virginia Foundation · 2025–2027
    MCVF 252199-02
  • MPI
    Clinical and Translational Science Center- Institutional CTSC Internal Funding UL1
    CTSC Cost Share · 2022–2027
    UL1TR002384-06
  • PI
    Biomarkers of response in primary mediastinal B-cell lymphoma: Defining tumor microenvironment signatures
    Hyundai Hope on Wheels Foundation · 2024–2026
    HHWF 240412-02
  • KP
    WWWW Foundation, Inc: COGFndn_NY018_2026_QuadW_CSBAO_Tissue Incentives
    WWWW Foundation INC dba QuadW · 2025–2026 · via Children's Oncology Group
    COG 264538
  • MPI
    Molecular Characterization of Primary Mediastinal B-cell Lymphoma to Identify Novel Biomarkers
    National Cancer Institute · 2025–2026 · via Public Health Institute
    UG1CA233249-06
  • MPI
    Risk Stratification using Tumor Microenviroment Signatures in Hodgkin Lymphoma
    Children's Oncology Group · 2022–2026
    COG 222649-02

Clinical research

5 studies

Active

4 studies
  • PI
    Real-World Experiences In Rare Pediatric, Adolescent, and Young Adult Lymphoma The "Umbrella Study"
    Ann & Robert H Lurie Childrens Hospital of Chicago · OPEN TO ACCRUAL (as of 2026)
  • PI
    Phase 2 Study of Tovorafenib (DAY101) in Relapsed and Refractory Langerhans Cell Histiocytosis
    PHASE2 · Children's Oncology Group · OPEN TO ACCRUAL (as of 2025)
    Recurrent Langerhans Cell Histiocytosis; Refractory Langerhans Cell Histiocytosis
    NCT05828069
  • PI
    A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy With Immuno-oncology Therapy for Children and Adults With Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
    PHASE3 · Children's Oncology Group · OPEN TO ACCRUAL (as of 2025)
    Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
    NCT05675410
  • PI
    Molecular analysis of lymphomas in children adolescents, and adults
    Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2024)
Completed & closed trials (1)
  • PI
    A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
    PHASE3 · Children's Oncology Group · CLOSED TO ACCRUAL (as of 2025)
    Primary Mediastinal Large B-Cell Lymphoma
    NCT04759586

News mentions

2 mentionsView all WCM news ↗